Research programme: anti-CD47 antibodies - Arch Oncology

Drug Profile

Research programme: anti-CD47 antibodies - Arch Oncology

Alternative Names: Ti 104; Ti 108; Ti 176

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vasculox
  • Developer Arch Oncology
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Jan 2018 Tioma Therapeutics is now called Arch Oncology
  • 12 Jan 2018 Pharmacodynamics data from a preclinical studies in Cancer and Breast cancer presented at at 40th Annual San Antonio Breast Cancer Symposium (SABCS 2107)
  • 05 Dec 2017 Preclinical trials in Breast cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top